RGNX241220C10000
- 0.95
- +0.30+46.15%
Regenxbio Newsroom
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $36
Buy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval Prospects
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
REGENXBIO Is Maintained at Buy by Chardan Capital
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
Regenxbio Analyst Ratings
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Stifel Nicolaus Sticks to Its Buy Rating for RegenXBio (RGNX)
A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $18 to $50
Promising Developments in RegenXBio's RGX-202 Program Drive Buy Rating
Morgan Stanley Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $22
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
Regenxbio Analyst Ratings
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $40
RegenXBio's Promising Gene Therapy Advancements and Strategic Financial Growth: A Buy Recommendation
REGENXBIO Is Maintained at Buy by Chardan Capital